Screener
Royalty Pharma RPRX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
Based on trailing twelve months.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
FAQ
- What is Royalty Pharma's return on equity?
- Royalty Pharma (RPRX) reported return on equity of 8.5% in Q2 2026.
- How has Royalty Pharma's return on equity changed year-over-year?
- Royalty Pharma's return on equity decreased by 20.5% year-over-year, from 10.6% to 8.5%.
- What is the long-term trend for Royalty Pharma's return on equity?
- Over 4 years (2020 to 2025), Royalty Pharma's return on equity has grown at a -24.3% compound annual growth rate (CAGR), from 23.5% to 7.7%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Royalty Pharma's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude